This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

6 Drug Stocks Unworthy of Biotech Bull Market

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Entremed (ENMD)

Stock return since Jan. 1: 198%

A biotech bubble wouldn't be complete without a new crop of investors "discovering" Entremed, the cancer-drug developer made famous -- or infamous -- by a New York Times front-page article in 1998. The article claimed Entremed was curing cancer by discovering two compounds that starved tumors of their blood supply. Less noticed was that Entremed's research at that time was only done on mice. Unfortunately, mice are cured of cancer all the time, people not so much. Although the scientific thesis underlying Entremed's research was later vindicated by the success and approval Genentech's Avastin, Entremed's own anti-cancer drug research flopped.

Entremed's record of drug-development futility is hard to match yet the company survives, always short of cash, always transitioning or re-inventing itself every few years. And like clockwork, when a new biotech bubble comes along, investors who know nothing of Entremed's checkered history start buying the stock again, insisting that this time, Entremed will be a winner.

Entremed shares closed Tuesday down 8% to $2.60.
6 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BPAX $55.05 -1.24%
ENMD $0.90 0.00%
CYTX $0.32 0.00%
GALE $1.38 0.00%
REGN $376.71 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs